Pfizer wins one, loses one on Prempro; J&J cuts max dosage of Tylenol;

@FiercePharma: Yervoy hits the market with $95M bang. Story | Follow @FiercePharma

> A West Virginia jury ruled for Pfizer in a Prempro lawsuit, rejecting allegations that the menopause drug caused a woman's breast cancer. Report

> Nevada's Supreme Court revived the state's deceptive trade practices lawsuit against Pfizer and two of its units, reinstating claims that the companies overstated the benefits of hormone-replacement drugs. Report

> Lupin signed on to market Eli Lilly's diabetes drugs, including the Huminsulin product range, in India and Nepal. Report

> Johnson & Johnson lowered the maximum recommended dose of Tylenol to help prevent overdoses and liver damage. Report

> GlaxoSmithKline CEO Andrew Witty pledged more hiring in U.K., thanks to recent tax-law changes. Report

> Matrix called Shire's Q2 results "outstanding" and reiterated its buy rating on the stock. Report

> PDL BioPharma saw second-quarter profits rise 40% to $70 million after it resolved a patent dispute with Novartis. Report

> Goldshield Pharmaceuticals is recalling a batch of Venaxx XL capsules because the patient information leaflet was left out of packages. Report

> Prescriptions grew by more than two-thirds in England over the last decade, with the average number dispensed per capita rising to 17.8 from 11.2. Report

> McKesson beat expectations with earnings of $1.27 per share, helped by a 9% rise in drug-distribution revenue. Report

Biotech News

@FierceBiotech: Baxter sets up $200M venture arm for early-stage investments. Item | Follow @FierceBiotech

@JohnCFierce: Merck is killing telcagepant, its migraine drug, after Ph3 data analysis. News | Follow @JohnCFierce

@RyanMFierce: More Biogen coverage to come after trip to Boston, but first catching up on pipeline priorities: Story | Follow @RyanMFierce

@MaureenFierce: New drugs trump mammograms for fewer cancer deaths. Article  | Follow @MaureenFierce

> After the R&D shakeout, Biogen aims to beef up drug pipeline. Story

> Amgen sees 26% jump in R&D spending. Article

> BDO: Biotechs continue to rein on R&D costs, focus on top prospects. Report

> FDA refuses to file Eisai app for new epilepsy drug. More

> Merck kills PhIII migraine drug program. Piece

> UK Scientists mount pioneering stem cell trial for MS. News

And Finally... A Tufts University psychiatry prof posits that the world's greatest leaders had mood disorders. Article

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.